Sigma Of Australia Loses Enough Market Value To Jeopardize Aspen Buy
This article was originally published in PharmAsia News
Executive Summary
Australia's Sigma Pharmaceuticals has lost so much of its stock-market value, a buyout offer by South Africa's Aspen Pharmacare Holdings may be in jeopardy